New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
06:41 EDTMYL, MDT, VRX, ABT, COVObama administration may restrict inversion tax benefits, NY Times says
The Obama administration is considering taking action on its own, without Congress, to restrict tax benefits for companies that execute inversions to reduce their tax bills, Treasury Secretary Jacob Lew said yesterday, according to The New York Times. Specifically, Treasury officials are compiling options that would allow the administration to eliminate the economic incentives for inversion deals, Lew said, the newspaper reported. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN Reference Link
News For MYL;ABT;MDT;COV;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 15, 2015
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
14:16 EDTABTAbbott announces 'favorable' data from MitraClip study
Subscribe for More Information
March 13, 2015
15:50 EDTVRXValeant announces HSR clearance for acquisition of Salix
Valeant Pharmaceuticals (VRX) announced that it has received early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to its proposed acquisition of Salix Pharmaceuticals (SLXP). The expiration of the waiting period satisfies one of the conditions to consummate the tender offer and Valeant expects to be in the position to close the transaction on April 1.
13:46 EDTVRXValeant to raise Salix bid above $160 per share after Endo entry, NYT says
In response to Endo (ENDP) making a rival bid for Salix (SLXP), Valeant Pharmaceuticals (VRX) now plans to team up with Bill Ackman's Pershing Square and other top shareholders to raises its bid for Salix to above $160 per share, all in cash, according to The New York Times, citing people briefed on the matter. The exact price of Valeantís raised offer was not yet known, the report stated. Salix shares are down about 1% to $168.88 in afternoon trading. Reference Link
13:43 EDTVRXValeant seen hiking Salix bid above $160 per share cash, NYT says
Subscribe for More Information
10:51 EDTMYLOptions with increasing implied volatility
Options with increasing implied volatility: PVA BBEP SLXP ENDP MYL BBBY TEVA ZTS
08:15 EDTVRXAckman says shares of Valeant 'very cheap'
Subscribe for More Information
08:14 EDTVRXAckman says does not view Endo bid for Salix as credible
Subscribe for More Information
08:13 EDTVRXAckman says Endo would be very highly levered with Salix deal
Bill Ackman of Pershing Square is speaking on CNBC.
08:11 EDTVRXAckman says Valeant CEO will not overpay for Salix
Bill Ackman of Pershing Square is speaking on CNBC.
05:56 EDTMYLStocks with implied volatility movement; MYL PBR
Subscribe for More Information
March 12, 2015
11:29 EDTVRXEndo repeats FY15 adjusted EPS view $4.35-$4.55, consensus $4.48
Subscribe for More Information
11:12 EDTVRXOptions with increasing implied volatility
Subscribe for More Information
09:32 EDTMDTMedtronic announces start of Resolute Onyx studies in U.S.
Medtronic announced the start of its Resolute Onyx Clinical Program in the United States, which will evaluate the Resolute Onyx drug-eluting stent in patients who have coronary artery disease. Included in the first phase of the study are patients with small vessels that would require a 2.0 mm stent, which until now, often were untreatable with a DES. Core sizes of the stent will be studied separately.
08:11 EDTVRXEndo offer for Salix unlikely to trump Valeant, says Leerink
Leerink believes Endo (ENDP) is unlikely to win the acquisition of Salix (SLXP) since Valeant's (VRX) offer is in all cash and Endo's shares sold off on the news, lessening the value of its buyout proposal. The firm says the estimated deal accretion of 15%-20% may not be enough to push up Endo's stock price.
08:09 EDTMYLTeva Mylan combination problematic for now, says Bernstein
Subscribe for More Information
07:57 EDTVRXValeant bid for Salix superior to Endo offer, says Canaccord
Subscribe for More Information
05:55 EDTVRXStocks with implied volatility movement; TEVA VRX
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use